ALLO – allogene therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Beneski Benjamin Machinas
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
Form 144 Allogene Therapeutics, Filed by: Chang David D
Form S-8 Allogene Therapeutics,
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.